Introduction
============

Dopamine, a precursor in the endogenous synthesis of norepinephrine, is the most commonly used medication to provide cardiovascular support in critically ill patients with low cardiac output state, via the stimulation of β1 and β2 adrenergic receptors.[@b1-cmc-6-2012-045],[@b2-cmc-6-2012-045] Often, these patients have impaired balance of oxygen transport and poor tissue perfusion. Therefore, in addition to improved cardiovascular state, the major goal of therapy in these patients is to improve the balance of systemic oxygen transport and tissue oxygenation by increasing systemic O~2~ delivery (DO~2~) relative to changes in systemic O~2~ consumption (VO~2~). In adult humans and animal experiments, the increase in DO~2~ induced by catecholamines is about 10-fold of the increase in VO~2~.[@b3-cmc-6-2012-045]--[@b5-cmc-6-2012-045]

However, in neonates, in contrast to that observed in adults and older children, dopamine worsens the balance of systemic oxygen transport by a greater increase in VO~2~ than DO~2~ as shown after cardiopulmonary bypass surgery.[@b6-cmc-6-2012-045] In neonatal lambs, dobutamine, a synthetic analog of dopamine, increases VO~2~ by 7--12 fold compared to older lambs, with a similar increase in DO~2~. The substantial increase in VO~2~ has been attributed to the abundant brown adipose tissue in neonates, which contains plentiful α, β~1~ and β~3~ adrenergic receptors.[@b7-cmc-6-2012-045],[@b8-cmc-6-2012-045] Stimulation of these receptors by catecholamines leads to non-shivering thermogenesis and a substantial increase in VO~2~.[@b7-cmc-6-2012-045],[@b9-cmc-6-2012-045],[@b10-cmc-6-2012-045] It has been shown that selective α~1~, β~1~ or β~2~-adrenoceptor blockade in newborn lambs does not affect the increases in VO~2~ or DO~2~ induced by dobutamine, but the combined adrenoceptor blockades markedly attenuated both VO~2~ and DO~2~.[@b3-cmc-6-2012-045]

β~3~-adrenergic receptor was discovered in 1970s and 1980s from pharmacological studies of rat adipocyte function, and is now known to be richly present in brown adipose tissue controlling of thermogenesis and energy balance.[@b8-cmc-6-2012-045],[@b11-cmc-6-2012-045],[@b12-cmc-6-2012-045] It has been shown that dopamine exerts a thermogenic effect on the brown adipose tissue and increases VO~2~ in rats.[@b10-cmc-6-2012-045] Selective β~3~-adrenoceptor antagonist, SR59230A,[@b13-cmc-6-2012-045] has been reported to down-regulate uncoupling protein-1 and norepinephrine induced cAMP accumulation,[@b13-cmc-6-2012-045],[@b14-cmc-6-2012-045] thus reduce thermogenesis in brown fat tissue in lambs.[@b15-cmc-6-2012-045] In addition, it has been found that β~3~-adrenergic receptors in the heart have negative inotropic properties. This has led to research investigating potential therapeutic applications to enhance cardiac contractility by blocking β~3~-adrenergic receptors in heart failure.[@b16-cmc-6-2012-045]

Therefore, we hypothesized that SR59230A may attenuate the increase in VO~2~ induced by dopamine, and maintain the inotropic effect, thus cardiac output (CO) and DO~2~, thereby improving the balance of systemic and myocardial oxygen transport in neonatal lambs.

Methods and Materials
=====================

Animal preparation
------------------

All experiments were conducted in accordance with guidelines and by approval of the Animal Care and Use Committee (Health Science), University of Alberta. Twelve mixed-breed newborn lambs 1 to 5 days of age weighing 2.5 to 5.0 kg were obtained from a local farm. Anesthesia was induced with isoflurane (2%--3%). After induction, isoflurane inhalation was ceased, and anesthesia was maintained with continuous i.v. infusion of fentanyl (5--10 μg/kg/h), midazolam (0.1--0.2 mg/kg/h) and pancuronium (0.05--0.1 mg/kg/h). Animals were intubated with a cuffed endotracheal tube to prevent any air leaks, and ventilated with FiO~2~ 0.3 and volume-cycled ventilation (SERVO VENTILATOR 300, Siemens Medical Systems, Solna, Sweden), a tidal volume of 10 mL/kg, rates of 20--30 breaths/min, and PEEP of 4 cm H~2~O. Systemic arterial blood gases were measured (iStat, Abbott Laboratories. Abbott Park, IL USA) and ventilation was adjusted to maintain pH 7.35--7.45, PaO~2~ 100--140 mmHg, and PaCO~2~ at 35--40 mmHg, while base deficits \>2 mmol/L were corrected with 22 mEq/L NaHCO~3~. Blood that had been collected from an adult donor lamb was used for blood transfusion at a rate of 20 to 30 mL/h.

Left femoral arterial, superior vena cava, coronary sinus catheters were inserted to monitor pressures, blood gases and to administer fluids and medications. Heart rate was measured (Hewlett Packard, Palo Alto, CA). Maintenance fluids consisted of 5% dextrose-saline at 10 mL/kg/h. Temperature was monitored by a rectal thermometer, and maintained above 37 °C by a heating pad and warm blankets, which were kept constant during the experimental period. A sternotomy was performed and the ductus arteriosus was ligated. An 8--10 mm diameter ultrasonic perivascular flow probe (Transonics Systems, Ithaca, New York, USA) was placed around the main pulmonary artery to continuously measure CO.

VO~2~ was continuously measured using respiratory mass spectrometry (AMIS2000 Innovision A/S, Odense, Denmark). This is highly sensitive, accurate and rapid method to allow simultaneous measurements of multiple gas fractions, and has been described previously.[@b17-cmc-6-2012-045] Stroke volume was calculated as CO/heart rate. DO~2~ was calculated as CO times arterial oxygen content (CaO~2~). Oxygen extraction ratio (ERO~2~) was calculated as VO~2~/DO~2~. All systemic hemodynamic and oxygen transport variables were indexed by weight as appropriate.

Myocardial oxygen and lactate extraction ratios (mERO~2~, mERlac, respectively) were calculated using standard equations:
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where CcsO~2~ indicates coronary sinus oxygen content.

Experimental protocol
---------------------

Lambs were randomized into two groups (n = 6 each) after a period of stabilization and baseline measurements of hemodynamics, oxygen transport and central temperature were obtained. Subsequently, the experimental (SR group) received an i.v. infusion of SR59230A at 5 mg/kg dissolved firstly in 0.5 mL DMSO, and then in 10 mL saline and an equal volume of the DMSO and saline, respectively, over 5 min. After 30 min, incremental dopamine i.v. infusions starting from 5 were increased to 10, 15, and 20 μg/kg/min sequentially every 15 minutes. Measurements were repeated before dopamine infusion and at the end of each dose of dopamine in both groups. At the end of the study, an over dose of phenobarbital was given for euthanasia.

Statistical analysis
--------------------

Data are expressed as mean ± SD. Mixed linear regression for repeated measures was used to compare the variables before and after SR59230A or saline infusion between the two groups. It was also used to compare the different levels of the variables and their trends of changes between groups over the incremental increases of dopamine, with analyses of the effects of group (*P*~group~) and dose (*P*~dose~) and the interaction between dose and group (*P*~group\*dose~). All data analysis was performed using SAS statistical software version 9.2 (SAS Institute Inc). A *P* value \<0.05 indicates a statistical significance.

Results
=======

There were no significant differences in age (mean 3 days old) and weight (4.0 ± 1.0 kg vs. 3.7 ± 0.6 kg) between the SR and Control groups, respectively.

Changes of the variables before and after SR 59230A/saline infusion in the two groups ([Table 1](#t1-cmc-6-2012-045){ref-type="table"} and [Fig. 1](#f1-cmc-6-2012-045){ref-type="fig"})
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All hemodynamic and oxygen transport variables were not significantly different at baseline between the two groups. Thirty minutes following SR59230A infusion, temperature and mean arterial pressure remained unchanged and were not different from those of Control group. Heart rate trended to decrease from 237 ± 33 beats/min to 202 ± 7 beats/min in SR group (*P* = 0.08). CO trended to decrease from 167 ± 31 ml/min/kg to 123 ± 8 mL/min/kg in SR group (*P* = 0.08). Stroke volume remained similar after SR59230A infusion within both groups. DO~2~, VO~2~, ERO~2~, mERO~2~ and mERlac did not change significantly in SR group. There were no significant changes in all the variables in Control group.

Changes of the variables over the incremental infusion of dopamine in the two groups ([Table 1](#t1-cmc-6-2012-045){ref-type="table"} and [Fig. 1](#f1-cmc-6-2012-045){ref-type="fig"})
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Over incremental doses of dopamine, temperature increased significantly in both groups (*P*~dose~ \< 0.0001); the rate of temperature increase was significantly less in SR group compared to Control group (*P*~dose\*group~ \< 0.005). There was no significant change in mean arterial pressure in either SR or Control group. Heart rate significantly increased in both groups (*P*~dose~ \< 0.05) to a similar degree (*P*~dose\*group~ \> 0.10). CO significantly increased in both groups (*P*~dose~ \< 0.005) to a similar degree (*P*~dose\*group~ \> 0.10). There was no significant change in stroke volume in both groups. DO~2~ trended to a small increase (*P*~dose~ = 0.08) due to a small but significant decrease in hemoglobin in both groups (*P*~dose~ = 0.04). VO~2~ increased significantly in both groups (*P*~dose~ \< 0.0001); however, the rate of VO~2~ increase was significantly less in SR group compared to Control group (*P*~dose\*group~ \< 0.0001). As a result, ERO~2~ increased significantly in both groups (*P*~dose~ \< 0.0001). The rate of overall increase in ERO~2~ was significantly less in SR group (*P*~dose\*group~ \< 0.0001), and it started to decrease at the incremental dose of dopamine from 10 to 20 ug/kg/min. mERO~2~ did not increase significantly in both groups (*P* \> 010). mERO~2~ was significantly lower in SR group (*P*~group~ = 0.01), with faster increase in SR groups compared to Control group (*P* \< 0.0001). mERlac decreased significantly in both groups (*P* = 0.04). mERlac levels trended to be higher (*P* = 0.08) with faster decrease over the doses of dopamine (*P* = 0.04).

Discussion
==========

This study demonstrates that in newborn lambs, SR59230A, a selective β~3~-adrenoreceptor antagonist, significantly attenuated the imbalance in systemic oxygen transport seen with incremental dopamine infusion. These increases in VO~2~ levels were significantly attenuated by SR59230A, whilst the increases in DO~2~ were not significantly different between the two groups. As a result, the balance of systemic and myocardial oxygen transport was improved, as indicated by the attenuated increase in ERO~2,~ lower mERO~2~ and higher mERlac.

The goal of dopamine and other catecholamine therapy is to improve the balance of systemic oxygen transport by a greater increase in DO~2~ relative to changes in VO~2~. Both circulatory and metabolic stimulating effects by catecholamines share the same adrenergic signaling mechanisms, mainly, β~1~ and β~2~ and α-adrenergic receptors. If the circulatory responses to adrenergic stimulation are reduced, or the metabolic response enhanced, the beneficial effects of catecholamines might be abrogated. Such is the case in neonatal subjects particularly those with myocardial injury and increased VO~2~ as seen after cardiopulmonary bypass surgery.[@b6-cmc-6-2012-045] It has been shown that α, β~1~, β~2~-adrenergic antagonists fail to improve the balance of oxygen transport, due to ineffective reduction of VO~2~ when each selectively used, or attenuation of both VO~2~ and DO~2~ to a similar degree when combined.[@b3-cmc-6-2012-045]

β~3~-adrenoreceptors also have both circulatory and metabolic effects, but distinctly different from other adrenergic receptors. In terms of metabolic effect, β~3~-adrenergic receptor are richly present in brown adipose tissue.[@b9-cmc-6-2012-045] Brown adipose tissue generates heat following stimulation of α-, β1-, particularly β~3~-adrenoreceptors by the sympathetic nervous system.[@b7-cmc-6-2012-045] It plays an essential role in non-shivering thermogenesis, hence VO~2~, in newborn humans and some in larger mammals including lambs. The ability to specifically activate or reduce energy expenditure via β~3~-adrenoreceptor manipulation is of much interest for the thermoregulation in newborns. Using the β~3~-adrenergic agonist Zeneca D7114 increased body temperature in moderately hypothermic Caesarean section-delivered lambs.[@b13-cmc-6-2012-045] Selective and potent β~3~-adrenoreceptor antagonist SR59230A has been shown to down-regulate uncoupling protein-1 and nor-epinephrine induced cAMP accumulation, thus reducing thermogenesis in brown adipose tissue in animal experiments including sheep models.[@b13-cmc-6-2012-045]--[@b15-cmc-6-2012-045] Our findings on the systemic effects of the attenuated rises in central body temperature and VO~2~ in newborn lambs treated with SR59230A prior to dopamine infusion are consistent with previous findings at tissue and molecular levels.[@b13-cmc-6-2012-045]--[@b15-cmc-6-2012-045] The improved balance of systemic oxygen transport may, at least partly, contribute the improved myocardial oxygen transport as indicated by the lower mERO~2~ and higher mERlac in lambs treated with SR59230A be attributed, at least partly, to the improved balance of systemic oxygen transport.

Nonetheless, the specific cardiac effect of SR59230A should also be accounted for. Compared to brown adipose tissue, β~3~-adrenoreceptors in the heart have been less extensively studied, but have gained increasing interest in recent years. It has been reported that β~3~-adrenoreceptor stimulation exerts a profound dose-dependent negative inotropic effect in ventricles with decreased myocardial contractility in humans and other species.[@b18-cmc-6-2012-045]--[@b20-cmc-6-2012-045] Hence, it is suggested that β~3~-adrenoreceptors serves as a "brake" during sympathetic overstimulation to antagonize β~1~-adrenoreceptors and β~2~-adrenoreceptors in the heart.[@b20-cmc-6-2012-045],[@b21-cmc-6-2012-045] In addition, β~3~-adrenoreceptor stimulation also exerts positive chronotropic effects, probably resulted from reflex mechanisms rather than from a direct stimulation of cardiac b3-adrenoceptors.[@b22-cmc-6-2012-045],[@b23-cmc-6-2012-045] It might be extrapolated that β~3~-adrenoreceptor antagonist may increase or maintain the inotropic effect of dopamine, thus myocardial contractility, but at the same time reduce the heart rate. As shown in our data, following SR59230A infusion, there was an immediate reduction in heart rate, but stroke volume was maintained. As a result, CO and DO~2~ decreased. Nonetheless, during incremental doses of dopamine infusion, the changes in heart rate, CO and stroke volume were not significantly different between the two groups. The lower heart rate and CO, thus reduced myocardial workload, might be attributable to the better balance of myocardial oxygen transport. It is important to note that, despite an initial reduction in heart rate and CO, the greater and continuous reduction in VO~2~ by SR59230A attenuated the imbalance of systemic oxygen transport at higher doses of dopamine infusion as indicated by the attenuated increase in ERO~2~.

Limitations
===========

There are several limitations in our study. First, stroke volume was used to reflect cardiac contractility. The changes in myocardial contractility in the experiment may be more accurately assessed with direct measurement utilizing techniques such as tissue Doppler by echocardiography[@b24-cmc-6-2012-045] or conductance catheter.[@b25-cmc-6-2012-045] Secondly, myocardial lactate extraction ratio reflects the overall balance of the complex production and consumption of lactate by myocardium. A high lactate extraction may indicate less lactate production or more lactate consumption, or both. The exact mechanism can only be shown by direct examination of myocardial metabolism. Nonetheless, based on the lower myocardial oxygen extraction ratio in lambs treated with SR59230A, the less lactate production may be likely the case in our study. Thirdly, we did not directly assess the regional changes in oxygen consumption in brown fat tissue. Therefore, the relationship between VO~2~ and brown fat tissue remains speculative in our study. Forth, this is a pilot study in healthy newborn lambs using only one dose of SR59230A. A dose response study in newborn lambs with myocardial injury and increased VO~2~, such as newborn subjects following cardiopulmonary bypass may provide more detailed and relevant information about the effects on SR59230A on VO~2~ and myocardial contractility, thus CO and DO~2~.

Conclusion
==========

Although β~3~-adrenoceptor antagonist SR59230A tends to induce an initial drop in heart rate and CO, it significantly attenuates the increase in VO~2~ and hence the imbalance of systemic and myocardial oxygen transport induced by dopamine at higher doses. Further studies are warranted to examine the dose response effect of SR59230A in subjects with myocardial injury and increased VO~2~ such as those after cardiopulmonary bypass surgery.
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![The changes of (**A**) heart rate, (**B**) cardiac output, (**C**) systemic oxygen delivery (DO~2~), (**D**) systemic oxygen consumption (VO~2~), and (**E**) oxygen extraction ratio (ERO~2~) prior to and following SR59230A infusion with incremental doses of dopamine. Control group received placebo of saline.\
**Notes:** *P*~dose~ indicates dopamine dose effect during dopamine infusion; and *P*~dose\*group~ indicates the difference in the rate of change between the two groups.](cmc-6-2012-045f1){#f1-cmc-6-2012-045}

###### 

Mean ± SD values of temperature, hemodynamics, and oxygen transport during the study protocol.

                      Pre-SR        Dopamine dose (μg/kg/min)                                                                           
  ------------------- ------------- -------------------------------------------------------- ------------- -------------- ------------- ----------------------------------------------------------------------------------------------------------
  Temperature (°C)                                                                                                                      
   Control group      37.4 ± 1      37.7 ± 1                                                 38.2 ± 1      38.5 ± 1       38.9 ± 1      39.1 ± 1[‡](#tfn3-cmc-6-2012-045){ref-type="table-fn"}
   SR group           38.1 ± 1      38.6 ± 1                                                 38.9 ± 1      39.1 ± 1       39.3 ± 1      39.3 ± 1[‡](#tfn3-cmc-6-2012-045){ref-type="table-fn"},[§](#tfn4-cmc-6-2012-045){ref-type="table-fn"}
  MAP (mmHg)                                                                                                                            
   Control group      65 ± 14       61 ± 14                                                  61 ± 14       62 ± 10        62 ± 10       67 ± 10
   SR group           73 ± 16       78 ± 7                                                   75 ± 8        70 ± 6         75 ± 10       73 ± 12
  HR (beats/min)                                                                                                                        
   Control group      223 ± 32      230 ± 28                                                 234 ± 29      227 ± 21       235 ± 22      242 ± 26
   SR group           237 ± 33      202 ± 16[†](#tfn2-cmc-6-2012-045){ref-type="table-fn"}   206 ± 17      205 ± 13       206 ± 15      208 ± 15
  Hb (g/dL)                                                                                                                             
   Control group      8.0 ± 1.1     8.1 ± 1.3                                                7.8 ± 1.2     7.5 ± 1.0      7.4 ± 1.1     7.4 ± 1.2[‡](#tfn3-cmc-6-2012-045){ref-type="table-fn"}
   SR group           8.1 ± 1.4     8.1 ± 1.2                                                7.9 ± 0.8     7.6 ± 0.9      7.5 ± 1.0     7.6 ± 1.2[‡](#tfn3-cmc-6-2012-045){ref-type="table-fn"}
  CO (mL/min/kg)                                                                                                                        
   Control group      169 ± 44      158 ± 21                                                 158 ± 34      170 ± 42       178 ± 42      176 ± 55
   SR group           167 ± 31      123 ± 21[†](#tfn2-cmc-6-2012-045){ref-type="table-fn"}   124 ± 24      132 ± 34       137 ± 38      147 ± 44
  SV (mL/beat/kg)                                                                                                                       
   Control group      0.8 ± 0.2     0.7 ± 0.2                                                0.7 ± 0.2     0.8 ± 0.2      0.8 ± 0.2     0.7 ± 0.2
   SR group           0.7 ± 0.2     0.6 ± 0.1                                                0.6 ± 0.2     0.7 ± 0.2      0.7 ± 0.2     0.7 ± 0.2
  DO~2~ (mL/min/kg)                                                                                                                     
   Control group      73 ± 21       70 ± 19                                                  66 ± 17       67 ± 12        68 ± 16       67 ± 18
   SR group           73 ± 19       54 ± 13                                                  51 ± 6        56 ± 13        59 ± 13       64 ± 16
  VO~2~ (mL/min/kg)                                                                                                                     
   Control group      11 ± 2.7      11 ± 1.3                                                 11 ± 1.9      12 ± 1.6       13 ± 1.1      14 ± 1.3[‡](#tfn3-cmc-6-2012-045){ref-type="table-fn"}
   SR group           12 ± 1.4      11 ± 1.9                                                 11 ± 1.9      11 ± 1.7       12 ± 1.8      12 ± 1.9[‡](#tfn3-cmc-6-2012-045){ref-type="table-fn"},[§](#tfn4-cmc-6-2012-045){ref-type="table-fn"}
  ERO~2~                                                                                                                                
   Control group      0.16 ± 0.03   0.16 ± 0.03                                              0.17 ± 0.04   0.219 ± 0.03   0.20 ± 0.05   0.23 ± 0.07[‡](#tfn3-cmc-6-2012-045){ref-type="table-fn"}
   SR group           0.18 ± 0.06   0.20 ± 0.06                                              0.22 ± 0.05   0.21 ± 0.08    0.20 ± 0.06   0.19 ± 0.06[‡](#tfn3-cmc-6-2012-045){ref-type="table-fn"},[§](#tfn4-cmc-6-2012-045){ref-type="table-fn"}
  mERO~2~                                                                                                                               
   Control group      0.61 ± 0.19   0.61 ± 0.10                                              0.65 ± 0.12   0.63 ± 0.09    0.67 ± 0.05   0.69 ± 0.06
   SR group           0.54 ± 0.19   0.55 ± 0.09                                              0.57 ± 0.06   0.60 ± 0.08    0.64 ± 0.08   0.67 ± 0.09[§](#tfn4-cmc-6-2012-045){ref-type="table-fn"}
  mERlac                                                                                                                                
   Control group      0.07 ± 0.10   0.13 ± 0.19                                              0.14 ± 0.09   0.04 ± 0.17    0.04 ± 0.22   0.01 ± 0.27
   SR group           0.10 ± 0.31   0.22 ± 0.27                                              0.22 ± 0.16   0.10 ± 0.10    0.11 ± 0.20   0.07 ± 0.18[§](#tfn4-cmc-6-2012-045){ref-type="table-fn"}

**Notes:**

*P* = 0.08 compared to Pre-SR values;

*P*~dose~ \< 0.05 for the change over incremental doses of dopamine;

*P*~group\*dose~ \< 0.05 for the interaction between group and dose of dopamine, indicating the difference in the rate of change over incremental doses of dopamine between the two groups.

**Abbreviations:** MAP, mean arterial pressure; HR, heart rate; CO, cardiac output; SV, stroke volume; DO~2~, oxygen delivery; VO~2~, oxygen consumption; ERO~2~, oxygen extraction ratio.
